{
    "nctId": "NCT05343117",
    "briefTitle": "Comparative Effectiveness of PAL Based-therapy as Initial ET Versus PAL Based-therapy After ChT for HR+/HER2- ABC",
    "officialTitle": "Comparative Effectiveness of Palbociclib Based-therapy as Initial Endocrine Therapy Versus Palbociclib Based-therapy After Chemotherapy for HR+/HER2- Advanced Breast Cancer in Chinese Clinical Practice: a Real-world Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Hormone Receptor Positive Advanced Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "Progression-free survival (PFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age \u2265 18 years, female (retrospective part);\n2. Histologically or cytologically confirmed recurrent or metastatic HR+/HER2- breast cancer, if there was metastatic pathology, the histological pathology of metastases should prevail (retrospective part);\n3. Received palbociclib in combination with endocrine therapy as initial therapy in the first line and received at least 1 cycle; or received systemic chemotherapy in the first line followed by sequential palbociclib in combination with endocrine therapy and received at least 1 cycle (retrospective part);\n4. The follow-up time was not less than 3 months after the initiation of palbociclib in combination with endocrine therapy (retrospective part);\n5. Age \u2265 18 years, female (prospective part);\n6. Histologically or cytologically confirmed recurrent or metastatic HR+/HER2- breast cancer, if there is metastatic pathology, the histological pathology of metastases should prevail (prospective part);\n7. ECOG PS \u2264 2, and expected survival of more than half a year and no life-threatening visceral metastasis (prospective part);\n8. Measurable disease (prospective part);\n9. No or up to 1 regimen of chemotherapy for advanced breast cancer (prospective part);\n10. The patient has good compliance, and needs to receive the treatment with the palbociclib-based therapy according to the condition (prospective part);\n11. Normal function of major organs and hematopoietic function, i.e. meeting the following criteria: Blood cell count criteria should be in accordance with: (no blood transfusion and blood products, no G-CSF and other hematopoietic stimulating factors for correction in recent 14 days): Hemoglobin (HB) \u2265 80 g/L; Neutrophils (ANC) \u2265 1.5 \u00d7 10\\^9/L; Platelet (PLT) \u2265 75 \u00d7 10\\^9/L. Liver function, renal function and electrolytes meeting the following criteria: Total bilirubin (TBIL) \\< 1.5 upper limit of normal (ULN), \u2264 3 ULN for patients with liver metastases; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 ULN, and \u2264 5 ULN for patients with liver metastases; Serum Cr \u2264 1.5 ULN or endogenous creatinine clearance \u2265 60 ml/min (Cockcroft-Gault formula); Electrolytes: magnesium \u2265 lower limit of normal (LLN) (prospective part);\n12. The patient is compliant and voluntarily accepts the treatment, follow-up visit, laboratory examination and other study procedures according to the doctor's prescription (prospective part).\n\nExclusion Criteria:\n\n1. \u2265 2 prior lines of chemotherapy for advanced breast cancer (retrospective part);\n2. Treatment with other CDK4/6 inhibitors (abemaciclib or ribociclib) or endocrine therapy only (retrospective part);\n3. Life-threatening visceral metastases, and lesions not evaluable for response (prospective part);\n4. Neutrophils \\< 1.5 \u00d7 10\\^9/L; platelets \\< 100 \u00d7 10\\^9/L; not improved after medication (prospective part);\n5. Total bilirubin \u2265 1.5 times the upper limit of normal, AST and ALT \u2265 2 times the upper limit of normal; serum Cr \u2265 1.5 times the upper limit of normal (prospective part);\n6. Have central nervous system or meningeal invasion (prospective part);\n7. Women who are pregnant, lactating, or planning to have children (prospective part);\n8. Received \u2265 2 prior lines of chemotherapy for advanced breast cancer (prospective part);\n9. Treatment with other CDK4/6 inhibitors (abemaciclib or ribociclib) or endocrine therapy only (prospective part);\n10. Concomitant poorly controlled serious illness, major surgery, or history of other malignancy within 5 years (prospective part);\n11. Other conditions that the investigator considers inappropriate for inclusion (prospective part).",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}